Anthony Petrone
Stock Analyst at Mizuho
(4.17)
# 475
Out of 5,113 analysts
211
Total ratings
56.49%
Success rate
12.17%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAS Exact Sciences | Downgrades: Neutral | $85 → $105 | $102.34 | +2.60% | 2 | Jan 20, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $18 → $21 | $20.15 | +4.22% | 2 | Dec 17, 2025 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $5.31 | +88.32% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $64.09 | +12.34% | 10 | Dec 17, 2025 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $60 → $72 | $67.89 | +6.06% | 7 | Dec 17, 2025 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $110 → $130 | $81.79 | +58.94% | 7 | Dec 17, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $75 → $90 | $67.87 | +32.61% | 16 | Dec 17, 2025 | |
| GH Guardant Health | Maintains: Outperform | $100 → $120 | $114.59 | +4.72% | 4 | Dec 17, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $85 → $90 | $64.95 | +38.57% | 9 | Dec 17, 2025 | |
| DXCM DexCom | Maintains: Outperform | $75 → $78 | $73.67 | +5.88% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $80.70 | +23.92% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $34.59 | +15.64% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $80.87 | +23.66% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $255.50 | +17.42% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $83.60 | +19.62% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.20 | +3.72% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $104.52 | +29.16% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $108.27 | +24.69% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $19.04 | -5.46% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $100.69 | -0.69% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $10.40 | +15.38% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $118.70 | +47.43% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $7.35 | +444.22% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $68.15 | -14.89% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $93.61 | +17.51% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $16.58 | -15.56% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $80.32 | +30.73% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $525.04 | -25.72% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $85.33 | -21.48% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $85.99 | +103.51% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $14.08 | +77.56% | 3 | May 13, 2020 |
Exact Sciences
Jan 20, 2026
Downgrades: Neutral
Price Target: $85 → $105
Current: $102.34
Upside: +2.60%
Tandem Diabetes Care
Dec 17, 2025
Maintains: Neutral
Price Target: $18 → $21
Current: $20.15
Upside: +4.22%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $5.31
Upside: +88.32%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $64.09
Upside: +12.34%
Lantheus Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $60 → $72
Current: $67.89
Upside: +6.06%
Inspire Medical Systems
Dec 17, 2025
Maintains: Outperform
Price Target: $110 → $130
Current: $81.79
Upside: +58.94%
Haemonetics
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $90
Current: $67.87
Upside: +32.61%
Guardant Health
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $114.59
Upside: +4.72%
Establishment Labs Holdings
Dec 17, 2025
Maintains: Outperform
Price Target: $85 → $90
Current: $64.95
Upside: +38.57%
DexCom
Dec 17, 2025
Maintains: Outperform
Price Target: $75 → $78
Current: $73.67
Upside: +5.88%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $80.70
Upside: +23.92%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $34.59
Upside: +15.64%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $80.87
Upside: +23.66%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $255.50
Upside: +17.42%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $83.60
Upside: +19.62%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.20
Upside: +3.72%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $104.52
Upside: +29.16%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $108.27
Upside: +24.69%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $19.04
Upside: -5.46%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $100.69
Upside: -0.69%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $10.40
Upside: +15.38%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $118.70
Upside: +47.43%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $7.35
Upside: +444.22%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $68.15
Upside: -14.89%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $93.61
Upside: +17.51%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $16.58
Upside: -15.56%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $80.32
Upside: +30.73%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $525.04
Upside: -25.72%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $85.33
Upside: -21.48%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $85.99
Upside: +103.51%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $14.08
Upside: +77.56%